145 results
8-K
PULM
Pulmatrix, Inc.
15 May 24
Regulation FD Disclosure
9:00am
-reviewed publication Headache: The Journal of Head and Face Pain. The Company undertakes no obligation to update, supplement or amend the materials
8-K
drjbsvnscqh
4 Mar 24
Regulation FD Disclosure
4:06pm
8-K
l81pu8 e0gu7w3
8 Jan 24
Entry into a Material Definitive Agreement
9:00am
8-K
vu44m xmk95hricu
11 Jul 23
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine
9:05am
8-K
oyf9cxy5
14 Nov 22
Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update
6:17am
8-K
vcp 23lntahgxzovc
26 Sep 22
Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine
9:00am
8-K
8tpa qr0rhi4i
12 Jul 22
Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine
9:00am